- Home
- BST vs ANAB Comparison
BST vs ANAB Comparison
Compare BST & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BST | ANAB |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | BST | ANAB |
|---|---|---|
| Price | $41.22 | $67.73 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $74.64 |
| AVG Volume (30 Days) | 95.6K | ★ 510.6K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 10.26% | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $234,603,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $52.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $30.02 | $17.11 |
| 52 Week High | $44.50 | $73.30 |
Technical Indicators
Market Signals| Indicator | BST | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 69.96 | 59.20 |
| Support Level | $41.00 | $53.46 |
| Resistance Level | $42.78 | N/A |
| Average True Range (ATR) | 0.80 | 3.85 |
| MACD | 0.55 | 0.34 |
| Stochastic Oscillator | 97.63 | 70.98 |
Price Performance
Historical ComparisonAbout BST BlackRock Science and Technology Trust of Beneficial Interest
BlackRock Science and Technology Trust is a closed-end management investment company. Its investment objectives are to provide total return and income through long-term capital appreciation.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).